ERALOP Study: Post Adjuvant FEC-Docetaxel Chemotherapy for Early Breast Cancer: Hair Regrowth in Real Life
May 2015
in “
Cancer research
”
Studysummary This study found that persistent significant alopecia was a common side effect following FEC-docetaxel chemotherapy, with a 33.4% global incidence, highlighting the need for awareness and potential preventative measures like cooling caps during treatment.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer